Literature DB >> 17151769

Effect of a prior authorization process on antiplatelet therapy and outcomes in patients prescribed clopidogrel following coronary stenting.

Margaret L Ackman1, Michelle M Graham, Carolyn Hui, Ross T Tsuyuki.   

Abstract

BACKGROUND: Alberta Blue Cross (ABC) provides copayment-based coverage for residents older than 65 years. A prior authorization (PA) process for patients prescribed clopidogrel following stent insertion was changed to an authorized prescriber (AP) list process in March 2002.
OBJECTIVE: To determine the effect of a policy change in medication coverage for clopidogrel on patients' filling of prescriptions and outcomes following stent insertion.
METHODS: Consecutive patients who received a coronary stent between September 1, 2001, and August 31, 2002, at the University of Alberta Hospital and were eligible for ABC coverage were identified. Data were obtained from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease and ABC databases.
RESULTS: One hundred twelve patients (45 in the PA period and 67 in the AP period) who received a coronary stent were eligible for ABC coverage during the study period. The two cohorts of patients were similar with respect to demographics. Fewer patients in the PA period than in the AP period had their prescription filled on the day of discharge (31% versus 54%; P=0.02), and the median time to fill was four days versus zero days in the PA and AP periods, respectively (Wilcoxon P=0.04). There was no significant difference in the proportion of patients filling their prescriptions after 28 days from discharge (67% versus 75%, P = not significant) or in the overall comparison of time to fill (log rank P=0.22). Two repeat revascularization procedures were necessary within six weeks after stent placement; both were in PA period patients who delayed or failed to fill their prescription.
CONCLUSIONS: The PA process may have delayed patients filling clopidogrel prescriptions following hospital discharge and has the potential to contribute to negative clinical consequences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151769      PMCID: PMC2569077          DOI: 10.1016/s0828-282x(06)70960-6

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  7 in total

1.  Improving the prior-authorization process to the satisfaction of customers.

Authors:  M Kielty
Journal:  Am J Health Syst Pharm       Date:  1999-08-01       Impact factor: 2.637

Review 2.  Effects of restrictive formularies in the ambulatory care setting.

Authors:  Joel Lexchin
Journal:  Am J Manag Care       Date:  2002-01       Impact factor: 2.229

3.  ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions.

Authors:  S C Smith; J T Dove; A K Jacobs; J W Kennedy; D Kereiakes; M J Kern; R E Kuntz; J J Popma; H V Schaff; D O Williams; R J Gibbons; J P Alpert; K A Eagle; D P Faxon; V Fuster; T J Gardner; G Gregoratos; R O Russell; S C Smith
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

4.  Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. On behalf of the APPROACH investigators.

Authors:  W A Ghali; M L Knudtson
Journal:  Can J Cardiol       Date:  2000-10       Impact factor: 5.223

5.  Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients.

Authors:  W E Smalley; M R Griffin; R L Fought; L Sullivan; W A Ray
Journal:  N Engl J Med       Date:  1995-06-15       Impact factor: 91.245

6.  Impact of NSAIDs prior authorization policy on patients' QoL.

Authors:  Aiman A Momani; S Suresh Madhavan; David P Nau
Journal:  Ann Pharmacother       Date:  2002-11       Impact factor: 3.154

7.  A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder.

Authors:  Jeffrey S McCombs; Lizheng Shi; Glen L Stimmel; Thomas W Croghan
Journal:  Clin Ther       Date:  2002-11       Impact factor: 3.393

  7 in total
  5 in total

1.  A pharmacist's guide to the 2012 update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy.

Authors:  Margaret L Ackman; Claudia Bucci; Michael Callaghan; Heather Kertland; Chantal Pharand; Patrick Robertson; William Semchuk
Journal:  Can Pharm J (Ott)       Date:  2015-03

Review 2.  Pharmaceutical policies: effects of restrictions on reimbursement.

Authors:  Carolyn J Green; Malcolm Maclure; Patricia M Fortin; Craig R Ramsay; Morten Aaserud; Stan Bardal
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

3.  A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.

Authors:  David N Juurlink; Tara Gomes; Dennis T Ko; Paul E Szmitko; Peter C Austin; Jack V Tu; David A Henry; Alex Kopp; Muhammad M Mamdani
Journal:  CMAJ       Date:  2009-01-28       Impact factor: 8.262

4.  Restrictive access to clopidogrel and mortality following coronary stent implantation.

Authors:  Odile Sheehy; Jacques LeLorier; Stéphane Rinfret
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

5.  Southern Saskatchewan Ticagrelor Registry experience.

Authors:  Payam Dehghani; Varun Chopra; Ali Bell; Sheila Kelly; Lori Zulyniak; Jeff Booker; Rodney Zimmermann; William Semchuk; Asim N Cheema; Andrea J Lavoie
Journal:  Patient Prefer Adherence       Date:  2014-10-16       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.